Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/6/2024 | Buy | TD Cowen | |
7/2/2024 | Outperform → Perform | Oppenheimer | |
6/4/2024 | $50.00 | Outperform | Oppenheimer |
5/24/2024 | $40.00 | Buy | Mizuho |
4/23/2024 | $2.00 → $54.00 | Buy | H.C. Wainwright |
4/23/2024 | $39.00 | Outperform | Leerink Partners |
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company's common stock with an exercise price of $19.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and we
Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $220.9M of cash, cash equivalents, and restricted cash as of September 30, 2024 expected to support planned operations, including completion of planned Phase
FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that safety and tolerability data from patients treated with Descartes-08 will be featured during a poster presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego. A copy of the abstract is available on the ASH website at www.hematology.org. Descartes-08, Cartesian's lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
S-8 - Cartesian Therapeutics, Inc. (0001453687) (Filer)
10-Q - Cartesian Therapeutics, Inc. (0001453687) (Filer)
8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up to at least six months observed in patients treated with Descartes-08 Safety profile continues to support outpatient administration Company expects to hold End-of-Phase 2 meeting with the FDA by year-end Company to host conference call today at 8:00 a.m. ET GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneerin
Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $220.9M of cash, cash equivalents, and restricted cash as of September 30, 2024 expected to support planned operations, including completion of planned Phase
Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2 trial of Descartes-08 IND filing for pediatric basket study of Descartes-08 with focus in neurology and rheumatology expected by year-end PIPE financing strengthened balance sheet, with net proceeds expected to support development of Descartes-08 in MG through planned Phase 3 trial GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today rep
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise at leading pharmaceutical organizations. "We are thrilled to welcome Dr. Malik, a proven leader and industry veteran, to our Board of Directors," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "His deep experience in successfully advancing innovative therapies through all st
SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb
HC Wainwright & Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $54 to $49.
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
TD Cowen initiated coverage of Cartesian Therapeutics with a rating of Buy
Oppenheimer downgraded Cartesian Therapeutics from Outperform to Perform
Oppenheimer initiated coverage of Cartesian Therapeutics with a rating of Outperform and set a new price target of $50.00